AFFYMAX (Stock Symbol: AFFY)
AFFY- Stock Profile
|Stock Ticker (Symbol):||AFFY|
|Traded Exchange:||NASDAQ Stock Exchange|
|Average Traded Price:||$0.96|
|Average Daily Traded Volume:||310,600|
|Started to Trade on:||Friday, December 15, 2006|
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. Affymax, Inc. has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California.